Valerio Therapeutics (ALVIO) Ratios

0 Followers

Valerio Therapeutics Ratios

FR:ALVIO's free cash flow for Q4 2024 was €-1.69. For the 2024 fiscal year, FR:ALVIO's free cash flow was decreased by € and operating cash flow was €-2.68. See a summary of the company’s cash flow.

Ratios	TTM	Jun 25	Dec 23	Dec 22	Dec 21
Liquidity Ratios
Current Ratio	―	0.25	1.17	2.88	4.27
Quick Ratio	―	0.25	1.17	2.77	4.06
Cash Ratio	―	0.06	0.61	2.04	2.53
Solvency Ratio	―	-0.48	-0.91	-0.94	-0.27
Operating Cash Flow Ratio	―	-0.68	-1.67	-1.32	-1.21
Short-Term Operating Cash Flow Coverage	―	-1.71	-12.85	-9.41	-2.90
Net Current Asset Value	€ ―	€ -21.63M	€ -7.47M	€ -237.00K	€ 10.01M
Leverage Ratios
Debt-to-Assets Ratio	―	0.75	0.26	0.23	0.19
Debt-to-Equity Ratio	―	-1.50	0.61	0.45	0.30
Debt-to-Capital Ratio	―	2.98	0.38	0.31	0.23
Long-Term Debt-to-Capital Ratio	―	-1.71	0.32	0.27	0.13
Financial Leverage Ratio	―	-2.01	2.38	1.93	1.61
Debt Service Coverage Ratio	―	-1.63	-12.20	-5.41	-1.43
Interest Coverage Ratio	―	-52.68	-307.39	-7.79	-6.04
Debt to Market Cap	―	1.12	0.37	0.32	0.34
Interest Debt Per Share	―	0.09	0.07	0.12	0.13
Net Debt to EBITDA	―	-1.02	-0.12	0.26	1.36
Profitability Margins
Gross Profit Margin	―	71.39%	70.39%	64.38%	90.94%
EBIT Margin	―	-1303.74%	-1121.50%	-1185.93%	-156.77%
EBITDA Margin	―	-672.73%	-1024.67%	-1180.67%	-144.19%
Operating Profit Margin	―	-919.63%	-1127.11%	-1186.07%	-180.38%
Pretax Profit Margin	―	-1313.61%	-1129.28%	-1335.62%	-186.66%
Net Profit Margin	―	-1334.69%	-1130.22%	-1355.65%	-146.16%
Continuous Operations Profit Margin	―	-1334.63%	-1130.11%	-1355.37%	-146.13%
Net Income Per EBT	―	101.60%	100.08%	101.50%	78.30%
EBT Per EBIT	―	142.84%	100.19%	112.61%	103.48%
Return on Assets (ROA)	―	-133.48%	-57.67%	-45.40%	-11.19%
Return on Equity (ROE)	―	267.98%	-137.41%	-87.84%	-18.02%
Return on Capital Employed (ROCE)	―	4041.42%	-84.03%	-47.63%	-15.93%
Return on Invested Capital (ROIC)	―	-228.54%	-78.26%	-45.67%	-14.82%
Return on Tangible Assets	―	-401.46%	-137.99%	-87.51%	-18.25%
Earnings Yield	―	-207.36%	-90.91%	-68.51%	-24.93%
Efficiency Ratios
Receivables Turnover	―	1.04	0.95	0.98	0.48
Payables Turnover	―	0.10	0.22	0.15	0.13
Inventory Turnover	―	0.00	88.83	0.69	0.25
Fixed Asset Turnover	―	1.53	1.18	0.76	1.82
Asset Turnover	―	0.10	0.05	0.03	0.08
Working Capital Turnover Ratio	―	-0.30	0.24	0.08	0.20
Cash Conversion Cycle	―	-3.38K	-1.29K	-1.55K	-602.36
Days of Sales Outstanding	―	352.58	384.26	374.11	767.38
Days of Inventory Outstanding	―	0.00	4.11	528.33	1.44K
Days of Payables Outstanding	―	3.73K	1.68K	2.45K	2.81K
Operating Cycle	―	352.58	388.37	902.43	2.21K
Cash Flow Ratios
Operating Cash Flow Per Share	―	-0.08	-0.14	-0.09	-0.10
Free Cash Flow Per Share	―	-0.08	-0.14	-0.09	-0.10
CapEx Per Share	―	<0.01	<0.01	<0.01	<0.01
Free Cash Flow to Operating Cash Flow	―	1.03	1.01	1.05	1.02
Dividend Paid and CapEx Coverage Ratio	―	-39.06	-101.62	-19.35	-61.67
Capital Expenditure Coverage Ratio	―	-39.06	-101.62	-19.35	-61.67
Operating Cash Flow Coverage Ratio	―	-0.93	-2.07	-0.94	-0.86
Operating Cash Flow to Sales Ratio	―	-6.95	-10.33	-6.54	-2.11
Free Cash Flow Yield	―	-110.73%	-83.92%	-34.78%	-36.58%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-0.48	-1.10	-1.46	-4.01
Price-to-Sales (P/S) Ratio	―	6.44	12.43	19.79	5.86
Price-to-Book (P/B) Ratio	―	-1.29	1.51	1.28	0.72
Price-to-Free Cash Flow (P/FCF) Ratio	―	-0.90	-1.19	-2.87	-2.73
Price-to-Operating Cash Flow Ratio	―	-0.93	-1.20	-3.02	-2.78
Price-to-Earnings Growth (PEG) Ratio	―	-0.07	0.07	>-0.01	<0.01
Price-to-Fair Value	―	-1.29	1.51	1.28	0.72
Enterprise Value Multiple	―	-1.97	-1.33	-1.41	-2.71
Enterprise Value	―	23.80M	24.56M	24.05M	15.86M
EV to EBITDA	―	-1.97	-1.33	-1.41	-2.71
EV to Sales	―	13.27	13.64	16.67	3.91
EV to Free Cash Flow	―	-1.86	-1.31	-2.42	-1.82
EV to Operating Cash Flow	―	-1.91	-1.32	-2.55	-1.85
Tangible Book Value Per Share	―	-0.13	-0.04	0.01	0.14
Shareholders’ Equity Per Share	―	-0.06	0.11	0.21	0.37
Tax and Other Ratios
Effective Tax Rate	―	-0.02	>-0.01	-0.01	-0.01
Revenue Per Share	―	0.01	0.01	0.01	0.05
Net Income Per Share	―	-0.16	-0.15	-0.18	-0.07
Tax Burden	―	1.02	1.00	1.01	0.78
Interest Burden	―	1.01	1.01	1.13	1.19
Research & Development to Revenue	―	2.87	5.38	7.66	1.21
SG&A to Revenue	―	1.48	1.45	1.83	0.58
Stock-Based Compensation to Revenue	―	0.22	0.29	0.50	0.06
Income Quality	―	0.52	0.91	0.48	1.44

Currency in EUR